Trenzyme receives approval for biosafety level 2 (BSL-2)

Konstanz, (PresseBox) - The Konstanz (Germany)-based Trenzyme GmbH just received approval for their biosafety level 2 (BSL-2) facility. Trenzyme is a biotech company offering a wide range of services in research and development for their customers. The company's core strengths are their cell line development as well as protein expression and purification businesses. Trenzyme offers exceptionally fast cell line development and employs expression systems from bacteria and yeast to insect and mammalian cells. Equally, the full range of molecular biology services is also available to their customers. By expanding their facility to accomodate BSL-2-classified projects Trenzyme once more guarantees their partners to stay ahead of the class.

Trenzyme GmbH

Trenzyme is a service provider offering customer specific solutions in the areas of molecular biology / biochemistry / generation of cell lines. Trenzyme's international clientele consists predominantly of pharmaceutical and biotech companies, for whom customized services have been provided successfully for more than 9 years.

Classical projects range from DNA cloning / gene synthesis / mutagenesis by means of expression in different systems (E.coli, yeast, insect cells, mammal cells) to protein purification.

Trenzyme is exclusively financed by private means and is constantly expanding its clientele. Over the last couple of years the company has experienced solid revenue growth.

Further Information is available at

Diese Pressemitteilungen könnten Sie auch interessieren

News abonnieren

Mit dem Aboservice der PresseBox, erhalten Sie tagesaktuell und zu einer gewünschten Zeit, relevante Presseinformationen aus Themengebieten, die für Sie interessant sind. Für die Zusendung der gewünschten Pressemeldungen, geben Sie bitte Ihre E-Mail-Adresse ein.

Es ist ein Fehler aufgetreten!

Vielen Dank! Sie erhalten in Kürze eine Bestätigungsemail.

Ich möchte die kostenlose Pressemail abonnieren und habe die Bedingungen hierzu gelesen und akzeptiert.